http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 21:04:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tenaya+Therapeutics%2C++++++For%3A+Jul+13++Filed+by%3A+Hyllengren+Eric+J/26769461.html si-local-file:///var/storage/secattach/20260714/26769461.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tenaya+Therapeutics%2C++++++For%3A+Jul+13++Filed+by%3A+Hyllengren+Eric+J/26769461.html Tue, 14 Jul 2026 21:04:00 -0400 O.34342580 TNYA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tenaya+Therapeutics%2C++++++For%3A+Jul+13++Filed+by%3A+Hyllengren+Eric+J/26769461.html si-local-file:///var/storage/secattach/20260714/26769461.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tenaya+Therapeutics%2C++++++For%3A+Jul+13++Filed+by%3A+Hyllengren+Eric+J/26769461.html Tue, 14 Jul 2026 21:04:00 -0400 O.34342580 TNYA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tenaya+Therapeutics%2C++++++For%3A+Jul+13++Filed+by%3A+Hyllengren+Eric+J/26769459.html si-local-file:///var/storage/secattach/20260714/26769459.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tenaya+Therapeutics%2C++++++For%3A+Jul+13++Filed+by%3A+Hyllengren+Eric+J/26769459.html Tue, 14 Jul 2026 21:01:00 -0400 O.34342580 TNYA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tenaya+Therapeutics%2C++++++For%3A+Jul+13++Filed+by%3A+Hyllengren+Eric+J/26769459.html si-local-file:///var/storage/secattach/20260714/26769459.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tenaya+Therapeutics%2C++++++For%3A+Jul+13++Filed+by%3A+Hyllengren+Eric+J/26769459.html Tue, 14 Jul 2026 21:01:00 -0400 O.34342580 TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Reports+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26769458.html <p>SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.</p> <p>The stock options have an exercise price of $0.8365 per share, which is equal http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Reports+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26769458.html Tue, 14 Jul 2026 21:00:00 -0400 O.34342580 TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Reports+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26769458.html <p>SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.</p> <p>The stock options have an exercise price of $0.8365 per share, which is equal http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Reports+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26769458.html Tue, 14 Jul 2026 21:00:00 -0400 O.34342580 TNYA http://www.streetinsider.com/Globe+Newswire/Tenaya+Therapeutics+Reports+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26769458.html <p>SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.</p> <p>The stock options have an exercise price of $0.8365 per share, which is equal http://www.streetinsider.com/Globe+Newswire/Tenaya+Therapeutics+Reports+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26769458.html Tue, 14 Jul 2026 21:00:00 -0400 O.34342580 TNYA http://www.streetinsider.com/Globe+Newswire/Tenaya+Therapeutics+Reports+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26769458.html <p>SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.</p> <p>The stock options have an exercise price of $0.8365 per share, which is equal http://www.streetinsider.com/Globe+Newswire/Tenaya+Therapeutics+Reports+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26769458.html Tue, 14 Jul 2026 21:00:00 -0400 O.34342580 TNYA http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Tenaya+Therapeutics+Inc+%28TNYA%29%3A+%27TN-301+Can+Become+a+Key+Value+Driver+for+TNYA%27/26733662.html <p>Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $40.00 price target on Tenaya Therapeutics Inc (NASDAQ: TNYA).</p><p>The analyst commented: "TN-301 Not Yet Valued But Can Become a Key Value Driver for TNYA: Here Is Why; Currently, Street does not value TNYA for TN-301, but we view the small molecule HDAC6 inhibitor developed in-house as a potentially major opportunity across various cardiovascular and orphan indications. Recognize, only 5 pan-HDAC inhibitors are approved whereas 6 HDAC6-specific inhibitors are in-development. Moreover, major deals have already taken place such as NVS' up-to $1.3B licensing agreement for PKN605 (HDAC6 inhibitor) in Ph2 for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Tenaya+Therapeutics+Inc+%28TNYA%29%3A+%27TN-301+Can+Become+a+Key+Value+Driver+for+TNYA%27/26733662.html Mon, 06 Jul 2026 09:33:43 -0400 TNYA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tenaya+Therapeutics%2C++++++For%3A+Jun+29/26729181.html si-local-file:///var/storage/secattach/20260702/26729181.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tenaya+Therapeutics%2C++++++For%3A+Jun+29/26729181.html Thu, 02 Jul 2026 17:00:00 -0400 O.34342580 TNYA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tenaya+Therapeutics%2C++++++For%3A+Jun+29/26729181.html si-local-file:///var/storage/secattach/20260702/26729181.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tenaya+Therapeutics%2C++++++For%3A+Jun+29/26729181.html Thu, 02 Jul 2026 17:00:00 -0400 O.34342580 TNYA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tenaya+Therapeutics%2C++++++For%3A+Jun+29/26702920.html si-local-file:///var/storage/secattach/20260629/26702920.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tenaya+Therapeutics%2C++++++For%3A+Jun+29/26702920.html Mon, 29 Jun 2026 09:00:00 -0400 O.34342580 TNYA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tenaya+Therapeutics%2C++++++For%3A+Jun+29/26702920.html si-local-file:///var/storage/secattach/20260629/26702920.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tenaya+Therapeutics%2C++++++For%3A+Jun+29/26702920.html Mon, 29 Jun 2026 09:00:00 -0400 O.34342580 TNYA http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html <p>Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, according to a company statement. He will oversee financial strategy, capital allocation, investor relations, and corporate development.</p> <p>Hyllengren brings more than two decades of experience in biotechnology finance, capital markets, and corporate strategy. He most recently served as CFO and Executive Vice President of Zura Bio. Before that, he was CFO and Chief Operating Officer at Atara Biotherapeutics, where he executed more than $500 million in public financings. Earlier in his career, he held roles across finance, investor relations, and business development over 15 years http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html Mon, 29 Jun 2026 08:32:53 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html <p>Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, according to a company statement. He will oversee financial strategy, capital allocation, investor relations, and corporate development.</p> <p>Hyllengren brings more than two decades of experience in biotechnology finance, capital markets, and corporate strategy. He most recently served as CFO and Executive Vice President of Zura Bio. Before that, he was CFO and Chief Operating Officer at Atara Biotherapeutics, where he executed more than $500 million in public financings. Earlier in his career, he held roles across finance, investor relations, and business development over 15 years http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html Mon, 29 Jun 2026 08:32:53 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html <p>Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, according to a company statement. He will oversee financial strategy, capital allocation, investor relations, and corporate development.</p> <p>Hyllengren brings more than two decades of experience in biotechnology finance, capital markets, and corporate strategy. He most recently served as CFO and Executive Vice President of Zura Bio. Before that, he was CFO and Chief Operating Officer at Atara Biotherapeutics, where he executed more than $500 million in public financings. Earlier in his career, he held roles across finance, investor relations, and business development over 15 years http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html Mon, 29 Jun 2026 08:32:53 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html <p>Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, according to a company statement. He will oversee financial strategy, capital allocation, investor relations, and corporate development.</p> <p>Hyllengren brings more than two decades of experience in biotechnology finance, capital markets, and corporate strategy. He most recently served as CFO and Executive Vice President of Zura Bio. Before that, he was CFO and Chief Operating Officer at Atara Biotherapeutics, where he executed more than $500 million in public financings. Earlier in his career, he held roles across finance, investor relations, and business development over 15 years http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html Mon, 29 Jun 2026 08:32:53 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html <p>Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, according to a company statement. He will oversee financial strategy, capital allocation, investor relations, and corporate development.</p> <p>Hyllengren brings more than two decades of experience in biotechnology finance, capital markets, and corporate strategy. He most recently served as CFO and Executive Vice President of Zura Bio. Before that, he was CFO and Chief Operating Officer at Atara Biotherapeutics, where he executed more than $500 million in public financings. Earlier in his career, he held roles across finance, investor relations, and business development over 15 years http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html Mon, 29 Jun 2026 08:32:53 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html <p>Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, according to a company statement. He will oversee financial strategy, capital allocation, investor relations, and corporate development.</p> <p>Hyllengren brings more than two decades of experience in biotechnology finance, capital markets, and corporate strategy. He most recently served as CFO and Executive Vice President of Zura Bio. Before that, he was CFO and Chief Operating Officer at Atara Biotherapeutics, where he executed more than $500 million in public financings. Earlier in his career, he held roles across finance, investor relations, and business development over 15 years http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html Mon, 29 Jun 2026 08:32:53 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html <p>Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, according to a company statement. He will oversee financial strategy, capital allocation, investor relations, and corporate development.</p> <p>Hyllengren brings more than two decades of experience in biotechnology finance, capital markets, and corporate strategy. He most recently served as CFO and Executive Vice President of Zura Bio. Before that, he was CFO and Chief Operating Officer at Atara Biotherapeutics, where he executed more than $500 million in public financings. Earlier in his career, he held roles across finance, investor relations, and business development over 15 years http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html Mon, 29 Jun 2026 08:32:53 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html <p>Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, according to a company statement. He will oversee financial strategy, capital allocation, investor relations, and corporate development.</p> <p>Hyllengren brings more than two decades of experience in biotechnology finance, capital markets, and corporate strategy. He most recently served as CFO and Executive Vice President of Zura Bio. Before that, he was CFO and Chief Operating Officer at Atara Biotherapeutics, where he executed more than $500 million in public financings. Earlier in his career, he held roles across finance, investor relations, and business development over 15 years http://www.streetinsider.com/Management+Changes/Tenaya+Therapeutics+names+Eric+Hyllengren+as+new+CFO/26702677.html Mon, 29 Jun 2026 08:32:53 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Appoints+Eric+Hyllengren+as+Chief+Financial+Officer/26702587.html <p align="justify">SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development.</p> <p align="justify">“We are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Appoints+Eric+Hyllengren+as+Chief+Financial+Officer/26702587.html Mon, 29 Jun 2026 08:30:00 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Appoints+Eric+Hyllengren+as+Chief+Financial+Officer/26702587.html <p align="justify">SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development.</p> <p align="justify">“We are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Appoints+Eric+Hyllengren+as+Chief+Financial+Officer/26702587.html Mon, 29 Jun 2026 08:30:00 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Appoints+Eric+Hyllengren+as+Chief+Financial+Officer/26702587.html <p align="justify">SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development.</p> <p align="justify">“We are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Appoints+Eric+Hyllengren+as+Chief+Financial+Officer/26702587.html Mon, 29 Jun 2026 08:30:00 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Appoints+Eric+Hyllengren+as+Chief+Financial+Officer/26702587.html <p align="justify">SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development.</p> <p align="justify">“We are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Appoints+Eric+Hyllengren+as+Chief+Financial+Officer/26702587.html Mon, 29 Jun 2026 08:30:00 -0400 A.09408455 A.50213484 A.50216686 O.02190753 O.34342580 O.36191329 O.38699866 TNYA